Trials / Active Not Recruiting
Active Not RecruitingNCT03381274
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 101 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Oleclumab | Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description. |
| DRUG | Osimertinib | Participants will receive osimertinib in combination with oleclumab as stated in the arms' description. |
| DRUG | AZD4635 | Participants will receive AZD4635 in combination with oleclumab as stated in the arms' description. |
Timeline
- Start date
- 2018-05-08
- Primary completion
- 2021-05-24
- Completion
- 2026-04-16
- First posted
- 2017-12-21
- Last updated
- 2026-03-11
- Results posted
- 2022-07-26
Locations
13 sites across 3 countries: United States, South Korea, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03381274. Inclusion in this directory is not an endorsement.